MGNX · Company research
MacroGenics, Inc. (MGNX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| A patient has received the first dose of a new cancer treatment. - Stock Titan | A patient has received the first dose of a new cancer treatment. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside - Stocktwits | MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? | MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? | MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance | Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. - Stock Titan | At $2.60 a share, MacroGenics (MGNX) research chief exercises options for 8,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| MacroGenics (MGNX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat | MacroGenics (MGNX) Short Interest & Short Float | Updated Sep 2026 MarketBeat | View source ↗ | MarketBeat | Sep 24, 2026 | neutral | 0 | 0.6 |
| Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale - Stock Titan | Former MacroGenics (NASDAQ: MGNX) officer lines up another stock sale Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance | Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 20, 2026 | neutral | 0 | 0.6 |
| MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses - Simply Wall Street | MacroGenics (MGNX) Stock Faces A Revenue Reality Check After Deeper Losses Simply Wall Street | View source ↗ | Simply Wall Street | Aug 16, 2026 | neutral | 0 | 0.6 |
| Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A - Stock Titan | Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance | MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| MacroGenics (MGNX) Stock Price, News & Analysis - 24/7 Wall St. | MacroGenics (MGNX) Stock Price, News & Analysis 24/7 Wall St. | View source ↗ | 24/7 Wall St. | Aug 13, 2026 | neutral | 0 | 0.6 |
| MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) - Seeking Alpha | MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important (MGNX) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 27, 2026 | neutral | 0 | 0.6 |
| MacroGenics slips after early-stage trial data for lead asset - Seeking Alpha | MacroGenics slips after early-stage trial data for lead asset Seeking Alpha | View source ↗ | Seeking Alpha | Jul 24, 2026 | neutral | 0 | 0.6 |
| MGNX Forecast — Price Target — Prediction for 2027 - TradingView | MGNX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.